Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan versus physician's choice first-line treatment for advanced or metastatic triple-negative breast cancer
NL-OMON59011Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-free survival. Started Nov 2022; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON59011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59011.